Biological Defense - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510243281

Publication Date:

October 24, 2024

Pages:

129

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.
The global market for Biological Defense was estimated to be worth US$ 1144 million in 2023 and is forecast to a readjusted size of US$ 1452.8 million by 2030 with a CAGR of 3.4% during the forecast period 2024-2030
The global biological defense market encompasses the products, technologies, and strategies aimed at detecting, protecting against, and responding to biological threats, including infectious diseases, bioterrorism, and pandemics. This market has gained significant attention and investment due to the increasing threat of biological agents and the need for effective defense and response mechanisms. Here are some key factors shaping the global biological defense market:
Emerging Infectious Diseases: The rise of emerging infectious diseases, such as Ebola, Zika, and most recently COVID-19, has heightened the awareness of the potential impact of biological threats on public health and security. This has led to increased investments in research, development, and deployment of biological defense systems.
Bioterrorism Threats: The persistent threat of bioterrorism, where intentional release of biological agents can cause harm to populations or disrupt societal systems, has necessitated the enhancement of defenses against biological attacks. Governments and organizations around the world are investing in countermeasures to mitigate the risk of bioterrorism incidents.
Technological Advancements: Advances in technology have significantly contributed to the development of more sophisticated and effective biological defense solutions. This includes rapid and accurate diagnostic tools, surveillance systems, biosensors, vaccines, therapeutics, and decontamination technologies.
Public and Private Sector Collaboration: Governments, defense agencies, and international organizations collaborate with private companies and research institutions to address biological defense challenges. Public-private partnerships play a crucial role in driving innovation and accelerating the development and deployment of biological defense solutions.
Regulatory Frameworks and Preparedness Strategies: Governments have implemented strategic plans and regulatory frameworks to enhance preparedness and response capabilities against biological threats. These frameworks focus on early detection, surveillance, risk assessment, threat intelligence, and coordination among agencies.
Global Health Security Initiatives: International organizations, such as the World Health Organization (WHO), World Organization for Animal Health (OIE), and World Customs Organization (WCO), work together to strengthen global health security and improve global coordination in preventing, detecting, and responding to biological threats.
Key players in the global biological defense market include pharmaceutical companies, biotechnology firms, diagnostic tool manufacturers, decontamination technology providers, and defense contractors. They are engaged in research, development, production, and distribution of products and solutions related to biological defense.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biological Defense, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Biological Defense by region & country, by Type, and by Application.
The Biological Defense market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biological Defense.
麻豆原创 Segmentation
By Company
SIGA Technologies
Ichor Medical Systems
Emergent BioSolutions
Elusys Therapeutics
DynPort Vaccine Company
Altimmune
Cleveland BioLabs
Bavarian Nordic
Alnylam Pharmaceuticals
Achaogen
Alexeter Technologies
ANP Technologies
PathSensors
New Horizons Diagnostics
BBI Detection
Segment by Type:
Anthrax
Small Pox
Botox
Other
Segment by Application
Military
Civilian
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Biological Defense manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Biological Defense in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Biological Defense in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Biological Defense Product Introduction
1.2 Global Biological Defense 麻豆原创 Size Forecast
1.3 Biological Defense 麻豆原创 Trends & Drivers
1.3.1 Biological Defense Industry Trends
1.3.2 Biological Defense 麻豆原创 Drivers & Opportunity
1.3.3 Biological Defense 麻豆原创 Challenges
1.3.4 Biological Defense 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Biological Defense Players Revenue Ranking (2023)
2.2 Global Biological Defense Revenue by Company (2019-2024)
2.3 Key Companies Biological Defense Manufacturing Base Distribution and Headquarters
2.4 Key Companies Biological Defense Product Offered
2.5 Key Companies Time to Begin Mass Production of Biological Defense
2.6 Biological Defense 麻豆原创 Competitive Analysis
2.6.1 Biological Defense 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Biological Defense Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biological Defense as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Anthrax
3.1.2 Small Pox
3.1.3 Botox
3.1.4 Other
3.2 Global Biological Defense Sales Value by Type
3.2.1 Global Biological Defense Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Biological Defense Sales Value, by Type (2019-2030)
3.2.3 Global Biological Defense Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Military
4.1.2 Civilian
4.1.3 Other
4.2 Global Biological Defense Sales Value by Application
4.2.1 Global Biological Defense Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Biological Defense Sales Value, by Application (2019-2030)
4.2.3 Global Biological Defense Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Biological Defense Sales Value by Region
5.1.1 Global Biological Defense Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Biological Defense Sales Value by Region (2019-2024)
5.1.3 Global Biological Defense Sales Value by Region (2025-2030)
5.1.4 Global Biological Defense Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Biological Defense Sales Value, 2019-2030
5.2.2 North America Biological Defense Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Biological Defense Sales Value, 2019-2030
5.3.2 Europe Biological Defense Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Biological Defense Sales Value, 2019-2030
5.4.2 Asia Pacific Biological Defense Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Biological Defense Sales Value, 2019-2030
5.5.2 South America Biological Defense Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Biological Defense Sales Value, 2019-2030
5.6.2 Middle East & Africa Biological Defense Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Biological Defense Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Biological Defense Sales Value
6.3 United States
6.3.1 United States Biological Defense Sales Value, 2019-2030
6.3.2 United States Biological Defense Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Biological Defense Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Biological Defense Sales Value, 2019-2030
6.4.2 Europe Biological Defense Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Biological Defense Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Biological Defense Sales Value, 2019-2030
6.5.2 China Biological Defense Sales Value by Type (%), 2023 VS 2030
6.5.3 China Biological Defense Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Biological Defense Sales Value, 2019-2030
6.6.2 Japan Biological Defense Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Biological Defense Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Biological Defense Sales Value, 2019-2030
6.7.2 South Korea Biological Defense Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Biological Defense Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Biological Defense Sales Value, 2019-2030
6.8.2 Southeast Asia Biological Defense Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Biological Defense Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Biological Defense Sales Value, 2019-2030
6.9.2 India Biological Defense Sales Value by Type (%), 2023 VS 2030
6.9.3 India Biological Defense Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 SIGA Technologies
7.1.1 SIGA Technologies Profile
7.1.2 SIGA Technologies Main Business
7.1.3 SIGA Technologies Biological Defense Products, Services and Solutions
7.1.4 SIGA Technologies Biological Defense Revenue (US$ Million) & (2019-2024)
7.1.5 SIGA Technologies Recent Developments
7.2 Ichor Medical Systems
7.2.1 Ichor Medical Systems Profile
7.2.2 Ichor Medical Systems Main Business
7.2.3 Ichor Medical Systems Biological Defense Products, Services and Solutions
7.2.4 Ichor Medical Systems Biological Defense Revenue (US$ Million) & (2019-2024)
7.2.5 Ichor Medical Systems Recent Developments
7.3 Emergent BioSolutions
7.3.1 Emergent BioSolutions Profile
7.3.2 Emergent BioSolutions Main Business
7.3.3 Emergent BioSolutions Biological Defense Products, Services and Solutions
7.3.4 Emergent BioSolutions Biological Defense Revenue (US$ Million) & (2019-2024)
7.3.5 Elusys Therapeutics Recent Developments
7.4 Elusys Therapeutics
7.4.1 Elusys Therapeutics Profile
7.4.2 Elusys Therapeutics Main Business
7.4.3 Elusys Therapeutics Biological Defense Products, Services and Solutions
7.4.4 Elusys Therapeutics Biological Defense Revenue (US$ Million) & (2019-2024)
7.4.5 Elusys Therapeutics Recent Developments
7.5 DynPort Vaccine Company
7.5.1 DynPort Vaccine Company Profile
7.5.2 DynPort Vaccine Company Main Business
7.5.3 DynPort Vaccine Company Biological Defense Products, Services and Solutions
7.5.4 DynPort Vaccine Company Biological Defense Revenue (US$ Million) & (2019-2024)
7.5.5 DynPort Vaccine Company Recent Developments
7.6 Altimmune
7.6.1 Altimmune Profile
7.6.2 Altimmune Main Business
7.6.3 Altimmune Biological Defense Products, Services and Solutions
7.6.4 Altimmune Biological Defense Revenue (US$ Million) & (2019-2024)
7.6.5 Altimmune Recent Developments
7.7 Cleveland BioLabs
7.7.1 Cleveland BioLabs Profile
7.7.2 Cleveland BioLabs Main Business
7.7.3 Cleveland BioLabs Biological Defense Products, Services and Solutions
7.7.4 Cleveland BioLabs Biological Defense Revenue (US$ Million) & (2019-2024)
7.7.5 Cleveland BioLabs Recent Developments
7.8 Bavarian Nordic
7.8.1 Bavarian Nordic Profile
7.8.2 Bavarian Nordic Main Business
7.8.3 Bavarian Nordic Biological Defense Products, Services and Solutions
7.8.4 Bavarian Nordic Biological Defense Revenue (US$ Million) & (2019-2024)
7.8.5 Bavarian Nordic Recent Developments
7.9 Alnylam Pharmaceuticals
7.9.1 Alnylam Pharmaceuticals Profile
7.9.2 Alnylam Pharmaceuticals Main Business
7.9.3 Alnylam Pharmaceuticals Biological Defense Products, Services and Solutions
7.9.4 Alnylam Pharmaceuticals Biological Defense Revenue (US$ Million) & (2019-2024)
7.9.5 Alnylam Pharmaceuticals Recent Developments
7.10 Achaogen
7.10.1 Achaogen Profile
7.10.2 Achaogen Main Business
7.10.3 Achaogen Biological Defense Products, Services and Solutions
7.10.4 Achaogen Biological Defense Revenue (US$ Million) & (2019-2024)
7.10.5 Achaogen Recent Developments
7.11 Alexeter Technologies
7.11.1 Alexeter Technologies Profile
7.11.2 Alexeter Technologies Main Business
7.11.3 Alexeter Technologies Biological Defense Products, Services and Solutions
7.11.4 Alexeter Technologies Biological Defense Revenue (US$ Million) & (2019-2024)
7.11.5 Alexeter Technologies Recent Developments
7.12 ANP Technologies
7.12.1 ANP Technologies Profile
7.12.2 ANP Technologies Main Business
7.12.3 ANP Technologies Biological Defense Products, Services and Solutions
7.12.4 ANP Technologies Biological Defense Revenue (US$ Million) & (2019-2024)
7.12.5 ANP Technologies Recent Developments
7.13 PathSensors
7.13.1 PathSensors Profile
7.13.2 PathSensors Main Business
7.13.3 PathSensors Biological Defense Products, Services and Solutions
7.13.4 PathSensors Biological Defense Revenue (US$ Million) & (2019-2024)
7.13.5 PathSensors Recent Developments
7.14 New Horizons Diagnostics
7.14.1 New Horizons Diagnostics Profile
7.14.2 New Horizons Diagnostics Main Business
7.14.3 New Horizons Diagnostics Biological Defense Products, Services and Solutions
7.14.4 New Horizons Diagnostics Biological Defense Revenue (US$ Million) & (2019-2024)
7.14.5 New Horizons Diagnostics Recent Developments
7.15 BBI Detection
7.15.1 BBI Detection Profile
7.15.2 BBI Detection Main Business
7.15.3 BBI Detection Biological Defense Products, Services and Solutions
7.15.4 BBI Detection Biological Defense Revenue (US$ Million) & (2019-2024)
7.15.5 BBI Detection Recent Developments
8 Industry Chain Analysis
8.1 Biological Defense Industrial Chain
8.2 Biological Defense Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Biological Defense Sales Model
8.5.2 Sales Channel
8.5.3 Biological Defense Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

SIGA Technologies
Ichor Medical Systems
Emergent BioSolutions
Elusys Therapeutics
DynPort Vaccine Company
Altimmune
Cleveland BioLabs
Bavarian Nordic
Alnylam Pharmaceuticals
Achaogen
Alexeter Technologies
ANP Technologies
PathSensors
New Horizons Diagnostics
BBI Detection

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.